Other Adenosine Our individual had multiple risk elements for developing an inhibitor: kind of mutation, main procedure, suggested to facilitate an antibody response against exogenous FVIII, initial and intensive contact with FVIII, and, potentially, continuous infusion of FVIII tuskonus March 8, 2022